Trial Profile

Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis
Focus Pharmacodynamics
Acronyms REVNEWANTICO

Most Recent Events

30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
31 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
02 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com